Current Report Filing (8-k)
10 January 2022 - 11:01PM
Edgar (US Regulatory)
0001178879
false
0001178879
2022-01-10
2022-01-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT PURSUANT TO
SECTION
13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): January 10, 2022
AMICUS THERAPEUTICS, INC.
(Exact
Name of Registrant as Specified in Its Charter)
|
Delaware
|
|
001-33497
|
|
71-0869350
|
|
(State
or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
Identification No.)
|
3675 Market Street,
Philadelphia, PA 19104
(Address of Principal
Executive Offices, and Zip Code)
215-921-7600
Registrant’s
Telephone Number, Including Area Code
(Former Name or Former Address, if Changed Since
Last Report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant
to Section 12(b) of the Act:
|
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
|
Common Stock Par Value $0.01
|
|
FOLD
|
|
NASDAQ
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR §240.12b-2). Emerging growth company ¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 – Results of Operations
and Financial Condition
On January 10, 2022, Amicus Therapeutics, Inc.
(the “Company”) issued a press release announcing preliminary 2021 revenue and its 2022 strategic outlook, along with various
business updates. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
herein by reference.
The information furnished pursuant to this Item
2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not
be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set
forth by specific reference in such filing.
Item 8.01 – Other Events
On January 10, 2022, the Company also published
presentation materials which senior management will be using in its meetings with investors and analysts at the 40th Annual J.P. Morgan
Healthcare Conference. A copy of these materials is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein
by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits:
Signature Page
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
|
AMICUS THERAPEUTICS, INC.
|
|
|
|
|
Date: January 10, 2022
|
By:
|
/s/ Ellen S. Rosenberg
|
|
|
Name: Ellen S. Rosenberg
|
|
|
Title: Chief Legal Officer and Corporate Secretary
|
Amicus Therapeutics (NASDAQ:FOLD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amicus Therapeutics (NASDAQ:FOLD)
Historical Stock Chart
From Apr 2023 to Apr 2024
